Brief: Shandong Boan Biotechnology Updates On Clinical Trials For Dulaglutide Injection In U.S.
05/08/2024 09:01
Aug 5 (Reuters) - Shandong Boan Biotechnology Co Ltd
6955.HK :
* APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR
DULAGLUTIDE
INJECTION (BA5101) IN U.S.
Further company coverage: 6955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil